Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Still a Buy?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares gapped up before the market opened on Tuesday . The stock had previously closed at $21.05, but opened at $21.68. Structure Therapeutics shares last traded at $20.36, with a volume of 67,221 shares changing hands.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on GPCR. William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating on the stock. JMP Securities reiterated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics currently has a consensus rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Stock Down 3.1 %

The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -27.44 and a beta of -2.37. The business’s fifty day moving average is $24.71 and its 200 day moving average is $31.63.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. Equities research analysts expect that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors have recently bought and sold shares of the company. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Structure Therapeutics in the fourth quarter valued at approximately $3,091,000. GF Fund Management CO. LTD. bought a new position in Structure Therapeutics in the fourth quarter valued at $34,000. Woodline Partners LP increased its stake in Structure Therapeutics by 0.7% in the 4th quarter. Woodline Partners LP now owns 333,901 shares of the company’s stock valued at $9,055,000 after buying an additional 2,328 shares during the last quarter. Vestal Point Capital LP lifted its position in Structure Therapeutics by 50.0% during the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $46,782,000 after buying an additional 575,000 shares in the last quarter. Finally, Twinbeech Capital LP boosted its stake in shares of Structure Therapeutics by 34.3% during the 4th quarter. Twinbeech Capital LP now owns 28,268 shares of the company’s stock worth $767,000 after buying an additional 7,220 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.